The combined therapy of GLP‐1 RAs with oral antihyperglycaemic medications (OAMs) or insulin has been increasingly accepted in the treatment of T2DM because this combination not only improves glycaemic control but also avoids weight gain and an increased risk of hypoglycaemia.70 The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.